Safety and efficacy with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received no prior antiecolony-stimulating factor 1 (CSF1) therapy: Ongoing phase II study

被引：0

作者：

Serrano, C. ^{[1
]}

Blay, J-Y. ^{[2
]}

Rutkowski, P. ^{[3
]}

Gelderblom, H. ^{[4
]}

Stacchiotti, S. ^{[5
]}

Falcon Gonzalez, A. ^{[6
,7
]}

Desai, J. ^{[8
]}

Le Cesne, A. ^{[9
]}

Ferraresi, V. ^{[10
]}

Palmerini, E. ^{[11
]}

Wilky, B. A. ^{[12
]}

Wagner, A. J. ^{[13
]}

Bernthal, N. M. ^{[14
]}

van de Sande, M. ^{[15
]}

Narasimhan, S. ^{[16
]}

Harrow, B. ^{[16
]}

Sharma, M. G. ^{[16
]}

Ruiz-Soto, R. ^{[16
]}

Sherman, M. L. ^{[16
]}

Tap, W. D. ^{[17
]}

机构：

[1] Vall dHebron Inst Oncol, Sarcoma Translat Res, Barcelona, Spain

[2] Ctr Leon Berard, Med, Lyon, France

[3] Maria Sklodowska Curie Natl Res Inst Oncol, Soft Tissue Bone Sarcoma & Melanoma, Warsaw, Poland

[4] Leiden Univ Med Ctr, Med Oncol, Leiden, Netherlands

[5] Fdn IRCCS Ist Nazl Tumori, Med Oncol, Milan, Italy

[6] Hosp Univ Virgen Rocio, Med Oncol, Seville, Spain

[7] Inst BioMed Sevilla, Seville, Spain

[8] Peter MacCallum Canc Ctr, Clin Res, Melbourne, Vic, Australia

[9] Gustave Roussy, Inst Cancerol, Villejuif, France

[10] IRCCS Ist Nazl Tumori Regina Elena, Sarcomas & Rare Tumors Dept Unit, Rome, Italy

[11] Ist Ortoped Rizzoli, DIMES Expt Diagnost & Specialty Med, Bologna, Italy

[12] Univ Colorado, Ctr Canc, Med Oncol, Aurora, CO USA

[13] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA

[14] Univ Calif Los Angeles, Orthopaed Surg, Los Angeles, CA USA

[15] Leiden Univ Med Ctr, Orthoped Oncol, Leiden, Netherlands

[16] Deciphera Pharmaceut LLC, Clin Dev, Waltham, MA USA

[17] Mem Sloan Kettering Canc Ctr, Sarcoma Med Oncol, 1275 York Ave, New York, NY 10021 USA

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.1860

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1769P

引用

页码：S1053 / S1053

页数：1

共 50 条

[31] A randomized phase II study of 500 mg/m2 and 1,000 mg/m2 of pemetrexed in patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had prior chemotherapy
Ichinose, Y.
Nakagawa, K.
Tamura, T.
Kubota, K.
Yamamoto, N.
Adachi, S.
Nambu, Y.
Nishiwaki, Y.
Saijo, N.
Fukuoka, M.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[32] Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study
Guo, Jun
Huang, Yiran
Zhang, Xu
Zhou, Fangjian
Sun, Yinghao
Qin, Shukui
Ye, Zhangqun
Wang, Hui
Jappe, Annette
Straub, Patrick
Pirotta, Nicoletta
Gogov, Sven
BMC CANCER, 2013, 13
[33] Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study
Jun Guo
Yiran Huang
Xu Zhang
Fangjian Zhou
Yinghao Sun
Shukui Qin
Zhangqun Ye
Hui Wang
Annette Jappe
Patrick Straub
Nicoletta Pirotta
Sven Gogov
BMC Cancer, 13
[34] A phase II, open-label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel cell carcinoma progressing on anti-PD-(L)1 antibody therapy: The MERKLIN 2 study.
Van Akkooi, Alexander Christopher Jonathan
Ascierto, Paolo Antonio
Nathan, Paul D.
Nghiem, Paul
Reimann, Philip
Hermann, Frank
Becker, Jurgen C.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[35] A multicenter, open-label, single-arm, phase II trial to evaluate the efficacy and safety of geptanolimab (GB226) in the treatment of patients (pts) with programmed cell death ligand 1 (PD-L1)-positive recurrent or metastatic cervical cancer, for whom prior platinum-containing chemotherapy has failed
An, Jusheng
Zhang, Yunyan
Feng, Mei
Zhang, Keqiang
Zhu, Jianqing
He, Aiqin
Li, Xiumin
Peng, Jin
Wang, Xinwen
Zhang, Hongping
Kong, Weimin
Li, Guiling
Yuan, Jianlin
Yu, Shiying
Liu, Hu
Ma, Cailing
Chen, Hongmin
Shen, Liangfang
Xie, Fan
Wu, Lingying
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[36] A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib
Richardson, Paul
Siegel, David
Baz, Rachid
Kelley, Susan L.
Munshil, Nikhil C.
Sullivan, Daniel
McBride, Laura
Doss, Deborah
Larkins, Gail
Jacques, Christian
Donaldson, Arlene
Anderson, Kenneth C.
BLOOD, 2009, 114 (22) : 126 - 127
[37] A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or In Combination with Low-Dose Dexamethasone In Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib
Richardson, Paul G.
Siegel, David
Baz, Rachid
Kelley, Susan L.
Munshi, Nikhil C.
Sullivan, Daniel
Alsina, Melissa
Doss, Deborah
McBride, Laura
Larkins, Gail
Lizza, Maria
Yu, Xin
Zaki, Mohamed
Jacques, Christian J.
Anderson, Kenneth C.
BLOOD, 2010, 116 (21) : 377 - 378
[38] MuTAR study, Phase II, open-label study of erlotinib (E) treatment in patients (pts) with locally advanced or metastatic non-small cell lung cancer (mNSCLC) who present activating mutations (MUT plus ) in the tyrosine kinase (TKI) domain of the epidermal growth factor receptor (EGFR), assessed the efficacy of 1L in Portuguese pts with mNSCLC EGFR Mut
Barata, F.
Queiroga, H.
Teixeira, E.
Almodovar, M. T.
Parente, B.
Soares, M.
REVISTA PORTUGUESA DE PNEUMOLOGIA, 2016, 22 (05) : 287 - 288
[39] A phase III study of MEDI4736 (M), an anti-PD-L1 antibody, in monotherapy or in combination with Tremelimumab (T), versus standard of care (SOC) in patients (pts) with advanced non-small cell lung cancer (NSCLC) who have received at least two prior systemic treatment regimens (ARCTIC).
Planchard, David
Shtivelband, Mikhail
Shi, Kelvin
Ibrahim, Ramy
Ballas, Marc
Soria, Jean-Charles
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[40] A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
Jaafar Bennouna
Istvan Lang
Manuel Valladares-Ayerbes
Katalin Boer
Antoine Adenis
Pilar Escudero
Tae-You Kim
Gillian M. Pover
Clive D. Morris
Jean-Yves Douillard
Investigational New Drugs, 2011, 29 : 1021 - 1028

← 1 2 3 4 5 →